Login or sign up
For business
Average ratingGreat
4.1/ 5

Based on 8 reviews

538%
438%
325%
20%
10%
Ask AI

Questions about MimiVax

Based on 8 reviews, listing data and website checks · updated 7 days ago

What is MimiVax?

MimiVax is a privately-held, clinical-stage biotechnology company headquartered in Buffalo, New York, that develops and commercializes immunotherapeutic vaccines and targeted therapies for cancer treatment.

How long has MimiVax existed and what is its team structure?

The company was founded in 2012 and has been operating for 15 years as of 2026, focusing on bench-to-bedside research to close the lab-to-clinic gap.

What specific product does MimiVax offer and what certifications does it have?

Their lead investigational product is SurVaxM, a survivin-targeting vaccine engineered specifically for glioblastoma, which holds Orphan Drug and Fast Track federal designations.

What is the mechanism behind MimiVax's vaccine technology?

The vaccine targets the survivin protein, a cell-survival protein present in most cancers, to enable healthcare providers to cure their patients.

What were the key results from the SURVIVE trial?

The SURVIVE Phase 2b trial showed that patients 65 and under lived a median of 24.2 months versus 20.2 months on placebo, achieving statistical significance in overall survival benefit.

How many patients were involved in the SURVIVE trial and what were the survival rates?

The trial included 233 patients, with 42% alive at 30 months or longer on SurVaxM compared to 18% on placebo for those 65 and under.

Where is MimiVax located and how does its location relate to its operations?

The company is located at Elm & Carlton Streets in Buffalo, NY, alongside the clinical environment where SurVaxM began.

How can patients and caregivers get started with MimiVax's services?

Patients and caregivers seeking expanded access to SurVaxM should start with the company's Expanded Access page, as requests outside of a clinical trial follow a separate process.

What is the current regulatory status of MimiVax's vaccine?

The website states that SurVaxM is an investigational product that has not been approved by the FDA or any other regulatory authority.

What is MimiVax's mission and what makes it different from competitors?

The company's mission is to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates.

What information does MimiVax provide to investors and medical professionals?

The company's website highlights that it provides information on its pipeline, clinical trials, and leadership team for investors and medical professionals.

What is the Trustburn rating and how recent are the reviews?

The Trustburn rating is 4.1 out of 5 from 8 reviews, with the most recent reviews from October 2023 praising the website's user-friendliness and exceptional services.

What do reviewers praise about MimiVax?

Reviewers consistently praised the website for being easy to navigate, informative, and user-friendly, while noting the company's professionalism and promptness.

How does MimiVax's approach differ from other glioblastoma therapies?

The company uses a survivin-targeting technology that is distinct from prior glioblastoma therapies that were adapted from other cancers.

What is the official website of MimiVax?

The official website of MimiVax is mimivax.com.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About MimiVax

MimiVax is a privately-held, clinical-stage biotechnology company that focuses on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. Its vaccines use survivin-targeting technology to target a cell-survival protein present in most cancers that enable healthcare providers to cure their patients.

The company was founded in 2012 and is headquartered in Buffalo, New York.